GIP and GLP-1 receptor co-agonist
Tirzepatide 12 mg injection once weekly
TIRZ_SC_12MG_QW
Related
- All doses pooled: Tirzepatide injection
- Tirzepatide 1 mg subcutaneous once weekly
- Tirzepatide 5 mg subcutaneous once weekly
- Tirzepatide 10 mg subcutaneous once weekly
- Tirzepatide 15 mg subcutaneous once weekly
- Tirzepatide maximum tolerated dose injection once weekly
- Tirzepatide subcutaneous once weekly, maximum tolerated dose: 10 or 15 mg
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.52 (0.01 to 37.89) | 0.46 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.20 (0.17 to 5.78) | 0.66 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.60 (0.01 to 43.17) | 0.56 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 4.74 (0.20 to 160) | 0.19 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 1.71 (0.10 to 16.03) | 0.49 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 2.42 (0.86 to 5.91) | 0.53 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.27 (0.96 to 10.31) | 0.44 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.78 (1.10 to 6.46) | 0.28 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.75 (0.06 to 4.33) | 0.69 |
| Type 2 diabetes (adults) | Discontinuation due to gastrointestinal adverse events | longest follow-up | Placebo | HR 2.51 (0.11 to 53.88) | 0.42 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.84 (0.05 to 13.98) | 0.48 |
| Type 2 diabetes (adults) | Pancreatic cancer | longest follow-up | Placebo | HR 0.83 (0.05 to 12.70) | 0.49 |